Trials of Gilead’s remdesivir in Covid-19 not diverse enough, experts write – MedCity News

In a commentary, physicians and pharmacists wrote that percentages of Black, Latino and Native American patients in two Phase III studies of the drug that the company is using for FDA approval were disproportionate to Covid-19’s incidence in those communities.

Read the full article here

Related Articles